Beijing Hotgen Biotech Co Ltd (688068) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beijing Hotgen Biotech Co Ltd (688068) has a cash flow conversion efficiency ratio of 0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥3.05 Million ≈ $446.80K USD) by net assets (CN¥2.93 Billion ≈ $428.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Beijing Hotgen Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Beijing Hotgen Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Beijing Hotgen Biotech Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Beijing Hotgen Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing Hotgen Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Corporativo GBM S.A.B. de C.V
MX:GBMO
|
-0.065x |
|
Vietnam Export Import Commercial Joint Stock Bank
VN:EIB
|
0.296x |
|
China Railway Construction Corporation Limited
F:4FF
|
0.046x |
|
Shanghai Film Co Ltd
SHG:601595
|
0.000x |
|
Immunocore Holdings Ltd
NASDAQ:IMCR
|
-0.011x |
|
Mitra Keluarga Karyasehat Tbk PT
JK:MIKA
|
0.041x |
|
Vinati Organics Limited
NSE:VINATIORGA
|
0.122x |
|
Nongshim
KO:004370
|
0.025x |
Annual Cash Flow Conversion Efficiency for Beijing Hotgen Biotech Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Beijing Hotgen Biotech Co Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Beijing Hotgen Biotech Co Ltd (688068) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.07 Billion ≈ $449.84 Million |
CN¥-37.16 Million ≈ $-5.44 Million |
-0.012x | -59.91% |
| 2023-12-31 | CN¥3.36 Billion ≈ $491.39 Million |
CN¥-25.39 Million ≈ $-3.71 Million |
-0.008x | -102.59% |
| 2022-12-31 | CN¥3.35 Billion ≈ $490.75 Million |
CN¥978.75 Million ≈ $143.22 Million |
0.292x | -68.28% |
| 2021-12-31 | CN¥2.87 Billion ≈ $420.53 Million |
CN¥2.64 Billion ≈ $386.97 Million |
0.920x | +317.43% |
| 2020-12-31 | CN¥746.79 Million ≈ $109.28 Million |
CN¥164.62 Million ≈ $24.09 Million |
0.220x | +638.85% |
| 2019-12-31 | CN¥649.30 Million ≈ $95.01 Million |
CN¥19.37 Million ≈ $2.83 Million |
0.030x | -88.59% |
| 2018-12-31 | CN¥210.44 Million ≈ $30.79 Million |
CN¥55.04 Million ≈ $8.05 Million |
0.262x | +84.21% |
| 2017-12-31 | CN¥161.65 Million ≈ $23.65 Million |
CN¥22.95 Million ≈ $3.36 Million |
0.142x | -59.17% |
| 2016-12-31 | CN¥130.98 Million ≈ $19.17 Million |
CN¥45.54 Million ≈ $6.66 Million |
0.348x | -- |
About Beijing Hotgen Biotech Co Ltd
Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers public safety solutions such as drug tasting, customs disease control, bioterrorism and food safety solutions. The company also provides clinical diagnostics and product solutions, inclu… Read more